Cobolimab
- Generic Name
- Cobolimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2022215-65-0
- Unique Ingredient Identifier
- 3K5H4TX2KP
- Background
Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).
- Associated Conditions
- -
- Associated Therapies
- -
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or ...
ANB032, a BTLA agonist, did not meet primary/secondary endpoints in ARISE-AD trial for atopic dermatitis; well tolerated with no safety signals. AnaptysBio to discontinue ANB032 investment, focusing on rosnilimab (PD-1+ T cell depleter/agonist) with Phase 2b RA data expected Feb 2025 and Phase 2 UC data in Q1 2026. Year-end 2024 cash estimated at $415M, extending runway to year-end 2027.
ANAPTYSBIO, INC SEC 10-Q Report
AnaptysBio's Q3 2024 10-Q report shows collaboration revenue up to $30.0M, with a net loss of $(32.9)M. The company advances its pipeline, including rosnilimab in Phase 2b for RA and UC, and ANB032 in Phase 2b for AD. Challenges include product development risks and regulatory approval hurdles.
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Top-line Phase 2b data for ANB032 (BTLA agonist) in atopic dermatitis expected Dec 2024, rosnilimab (PD-1 agonist) in rheumatoid arthritis in Feb 2025. Phase 1 trial initiated for ANB033 (anti-CD122 antagonist). Cash runway reiterated through year-end 2026.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath